-
2023-507342-84-00
5
2021-10-26
Bladder Cancer
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2024-513091-17-00
5
2021-09-29
Progressive myopia
-
2024-512038-13-00
5
2021-09-16
Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
-
2024-516959-40-00
4
2021-08-17
This trial evaluates the efficacy and safety of Mirvetuximab soravtans
-
2023-506270-13-00
4
2021-07-27
Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
-
2024-512978-99-00
4
2021-07-19
Chronic graft versus host disease (cGVHD)
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-510389-28-00
5
2021-06-14
short bowel syndrome
-
2024-513527-17-00
4
2021-06-07
Multiple Sclerosis
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2023-503995-26-00
5
2021-05-11
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507970-42-00
5
2021-03-31
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2024-518033-28-00
6
2020-11-27
Prophylaxis of transplant rejection in adult liver allograft recipient
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2022-502084-38-00
5
2020-10-16
Cancer